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Background
In patients with chronic hepatitis C (CHC), liver fibrosis is
a complex process, not completely understood, resulting
from the activation of hepatic stellate cells and a pro-
inflammatory status.
We aimed to evaluate the inflammation patterns in
patients with CHC and the correlations between the
inflammatory biomarkers and liver fibrosis.
Methods
We performed a cross-sectional study on patients with
CHC, in a tertiary-care hospital in November 2011 –
April 2012. We staged liver fibrosis using FibroMax
(BioPredictive) and we used CobasTaqman (Roche) for
HCV-RNA quantification. Patients were also evaluated
by ALT, platelets, erythrocyte sedimentation rate (ESR),
fibrinogen, C-reactive protein (CRP) and tumor necrosis
factor alpha (TNFa) plasma levels. For TNFa quantifica-
tion we used Kamiya Biomedical Company ELISA kits.
Results
We enrolled 76 patients with CHC (sex ratio M/F 0.6/1,
median age 51 [44-58] years). According to the FibroMax
evaluation, most of the patients had F0 fibrosis (25%,
n=19), F2 fibrosis (42%, n=32) and F4 fibrosis (16%, n=12)
respectively. The median HCV-RNA was 5 [5-5.75] log10.
History of previous HCV-therapy with pegIFN and riba-
virin was recorded in 75% (n=57) of patients and half of
them had a sustained virological response.
The inflammatory biomarkers displayed the following
patterns: median ESR 12 [8-22.5] mm/h, median fibrinogen
295 [254-343] mg/dL, median CRP 0.55 [0.2-1.5] mg/L,
median TNF alpha 6.38 [4.75-9.33] pg/mL.
Comparing the patients without fibrosis (F0) with the
patients with fibrosis (F1-F4), we found a significant dif-
ference between TNFa values (patients with F0 - median
TNFa 5.5 [4.0-7.1] pg/mL; patients with F1-F4 – median
TNFa 7.3 [5.0-10.6]; p<0.001). In patients with fibrosis,
we found a moderate correlation between TNFa values
and fibrosis score, according to the FibroMax score
(rho=0.4, p=0.002) and between TNFa values and ALT
(rho=0.43, p=0.001).
Conclusion
In patients with CHC, liver fibrosis is correlated with the
levels of TNFa, as a biomarker of systemic inflammation.
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